IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®
The Society of Interventional Oncology (SIO) has petitioned the National Comprehensive Cancer Network (NCCN) to include cryoablation in its Breast Cancer Guidelines, specifically citing IceCure’s FDA clearance of the ProSense system. The petition recommends a Category 2B option for patients aged 70+ and seeks to expand eligibility to patients aged 50-69 who are poor surgical candidates.
Key figures
- Clearance date
- October 2025
- Tumor size limit
- 1.5 cm
- Patient age primary
- 70+
- Patient age expansion
- 50-69
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.